Based on our current understanding of the differential effects of CD137-CD137L manipulation in major organ manifestation in SLE, the next sensible step would be an evaluation of the clinical safety and efficacy of the therapeutic CD137 and/or CD137L manipulation in different subsets of SLE patients in accordance to their clinical manifestations. The gene discussed is TNFSF9; the disease is systemic lupus erythematosus.